The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License ...

Zilovertamab vedotin is Merck’s investigational antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). Global recruitment of the waveLINE-010 trial ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

The therapy includes brentuximab vedotin, lenalidomide, and a rituximab product, targeting patients who failed two or more prior systemic therapies. Approval is based on the phase 3 ECHELON-3 ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma. Feasibility and efficacy of ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Among patients with upper tract urothelial carcinoma (UTUC) lesions, the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) resulted in promising clinical activity, study results ...